MX390835B - Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes - Google Patents
Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientesInfo
- Publication number
- MX390835B MX390835B MX2017009913A MX2017009913A MX390835B MX 390835 B MX390835 B MX 390835B MX 2017009913 A MX2017009913 A MX 2017009913A MX 2017009913 A MX2017009913 A MX 2017009913A MX 390835 B MX390835 B MX 390835B
- Authority
- MX
- Mexico
- Prior art keywords
- arsenic
- lyophilized compositions
- malignancies
- relates
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al tratamiento de malignidades tales como tumores o cánceres por medio de administración oral de composiciones liofilizadas que comprenden arsénico a un sujeto en tal necesidad. Las malignidades incluyen diferentes malignidades hematológicas, tales como leucemia mieloide aguda (AML) incluyendo leucemia promielocítica aguda (APL), síndrome mielodisplásico (MDS), mieloma múltiple (MM) y linfomas y tumores sólidos incluyendo glioblastoma multiforme y cáncer de mama. El tratamiento de arsénico ha mostrado ser muy prometedor en el tratamiento de varios cánceres pero requiere la administración intravenosa (IV) diaria. Esta invención se refiere a una formulación novedosa que comprende una composición liofilizada que comprende arsénico. Como resultado, la formulación facilita una biodisponibilidad sistémica comparable con la de la administración intravenosa (IV) de trióxido de arsénico que se practica actualmente. La presente invención también se refiere a un método para liofilizar el trióxido de arsénico, preparar la formulación oral que comprende composiciones liofilizadas que comprenden arsénico, y un método para tratar a un sujeto con malignidades utilizando la formulación oral.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562110574P | 2015-02-01 | 2015-02-01 | |
| US201562142709P | 2015-04-03 | 2015-04-03 | |
| PCT/US2016/015917 WO2016123603A2 (en) | 2015-02-01 | 2016-02-01 | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017009913A MX2017009913A (es) | 2018-08-15 |
| MX390835B true MX390835B (es) | 2025-03-21 |
Family
ID=56544541
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017009913A MX390835B (es) | 2015-02-01 | 2016-02-01 | Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes |
| MX2020012611A MX2020012611A (es) | 2015-02-01 | 2017-07-31 | Composiciones liofilizadas de alta area de superficie que comprenden arsenico para administracion oral en pacientes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012611A MX2020012611A (es) | 2015-02-01 | 2017-07-31 | Composiciones liofilizadas de alta area de superficie que comprenden arsenico para administracion oral en pacientes. |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US10111836B2 (es) |
| EP (3) | EP4599823A1 (es) |
| JP (3) | JP6928768B2 (es) |
| CN (2) | CN117899029A (es) |
| AU (4) | AU2016211186A1 (es) |
| CA (2) | CA2975406C (es) |
| DK (1) | DK3981414T3 (es) |
| ES (2) | ES2899226T3 (es) |
| FI (1) | FI3981414T3 (es) |
| HR (1) | HRP20251032T1 (es) |
| HU (1) | HUE072537T2 (es) |
| LT (1) | LT3981414T (es) |
| MX (2) | MX390835B (es) |
| PL (1) | PL3981414T3 (es) |
| PT (1) | PT3981414T (es) |
| RS (1) | RS67133B1 (es) |
| SI (1) | SI3981414T1 (es) |
| SM (1) | SMT202500321T1 (es) |
| TW (3) | TW202337477A (es) |
| WO (1) | WO2016123603A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260027056A1 (en) * | 2015-02-01 | 2026-01-29 | Quetzal Therapeutics, Llc | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| EP4599823A1 (en) | 2015-02-01 | 2025-08-13 | Quetzal Therapeutics, LLC | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
| ES2964979T3 (es) | 2016-12-01 | 2024-04-10 | Eupharma Pty Ltd | Composiciones de arsénico |
| KR101844049B1 (ko) | 2016-12-05 | 2018-03-30 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물 |
| KR101844050B1 (ko) | 2016-12-09 | 2018-05-14 | 주식회사 케마스 | 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물 |
| ES3009748T3 (en) * | 2017-01-18 | 2025-03-31 | Inst Nat Sante Rech Med | Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| US12582984B1 (en) | 2020-07-02 | 2026-03-24 | Argonaut Manufacturing Services, Inc. | Method for lyophilization and device thereof |
| US11583552B2 (en) * | 2021-02-17 | 2023-02-21 | Manoj Maniar | Pharmaceutical formulation of arsenic trioxide |
| JP7428842B1 (ja) | 2023-03-29 | 2024-02-06 | ａｒｔｉｅｎｃｅ株式会社 | 活性エネルギー線硬化型インキ、その製造方法、および印刷物 |
| WO2025172482A1 (en) * | 2024-02-14 | 2025-08-21 | Institut Gustave Roussy | Oral composition of arsenic trioxide for cancer treatment |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773419A (en) | 1995-03-03 | 1998-06-30 | Falcon; Juan | Method of treating cancer with tannic acid |
| CN1044559C (zh) * | 1995-08-23 | 1999-08-11 | 哈尔滨医科大学附属第一医院 | 抗白血病、肝癌、淋巴瘤注射液 |
| IL136051A0 (en) | 1997-11-10 | 2001-05-20 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| US7276359B1 (en) * | 1998-03-13 | 2007-10-02 | Wyeth | Polynucleotide composition, method of preparation, and use thereof |
| CN1131922C (zh) | 1998-10-19 | 2003-12-24 | 张在喆 | 一种通过弹性键搭架与收拢的帐篷 |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| CN1813753B (zh) * | 2000-02-29 | 2010-04-07 | 布里斯托尔-迈尔斯斯奎布公司 | 低剂量艾替开韦制剂及其应用 |
| AUPR874601A0 (en) * | 2001-11-08 | 2001-11-29 | Unisearch Limited | Selective targeting of apoptotic cells |
| US7521071B2 (en) * | 2002-10-09 | 2009-04-21 | Versitech Limited | Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| US8906422B2 (en) | 2002-10-09 | 2014-12-09 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| GB0315632D0 (en) * | 2003-07-04 | 2003-08-13 | West Pharm Serv Drug Res Ltd | Pharmaceutical formulations |
| CN1251688C (zh) | 2003-12-09 | 2006-04-19 | 重庆维特瑞医药开发有限公司 | 三氧化二砷冻干粉针及其生产方法 |
| JP4292985B2 (ja) | 2003-12-25 | 2009-07-08 | Ｊｓｒ株式会社 | 感放射線性組成物、マイクロレンズとその形成方法および液晶表示素子 |
| CN1698650A (zh) | 2004-05-21 | 2005-11-23 | 哈尔滨伊达药业有限公司 | 一种治疗原发性肝癌的亚砷酸注射液及其制备方法 |
| CN1326528C (zh) | 2004-07-13 | 2007-07-18 | 东南大学 | 砒霜磁性纳米明胶微球的制备工艺 |
| WO2007069272A2 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| WO2008046299A1 (en) * | 2006-10-11 | 2008-04-24 | The University Of Hong Kong | Method for inhibiting cancer using arsenic trioxide |
| CN101322719B (zh) * | 2007-06-15 | 2012-03-07 | 杭州民生药业有限公司 | 一种三氧化二砷固体脂质纳米粒及其制剂 |
| US8168224B2 (en) * | 2007-12-19 | 2012-05-01 | Beijing Shengyiyao Science & Technology Development Co., Ltd. | Sodium alginate microsphere vascular embolus containing water-soluble drug and preparation and application thereof |
| KR101455446B1 (ko) | 2008-09-19 | 2014-10-27 | 액티버스 파마 컴퍼니 리미티드 | 의료용 복합 유기 화합물 분체, 그 제조 방법 및 현탁액 |
| EP2525783A1 (en) | 2010-01-18 | 2012-11-28 | Cephalon France | Improved oral lysophilisates containing pvp/va |
| EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
| CN103142648B (zh) * | 2011-12-07 | 2015-04-15 | 浙江中医药大学 | 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂 |
| CN103408477B (zh) | 2013-08-22 | 2015-06-10 | 陈鹏飞 | 一种含砷配位化合物及其制备方法 |
| PL3250213T3 (pl) | 2015-01-29 | 2023-10-30 | Eupharma Pty Ltd | Kompozycje zawierające arsen do stosowania w sposobach leczenia |
| EP4599823A1 (en) | 2015-02-01 | 2025-08-13 | Quetzal Therapeutics, LLC | High surface-area lyophilized compositions comprising arsenic for oral administration in patients |
-
2016
- 2016-02-01 EP EP25184422.1A patent/EP4599823A1/en active Pending
- 2016-02-01 CN CN202311663020.2A patent/CN117899029A/zh active Pending
- 2016-02-01 TW TW111149127A patent/TW202337477A/zh unknown
- 2016-02-01 CA CA2975406A patent/CA2975406C/en active Active
- 2016-02-01 SI SI201631917T patent/SI3981414T1/sl unknown
- 2016-02-01 CN CN201680020478.8A patent/CN107530373B/zh active Active
- 2016-02-01 HU HUE21192594A patent/HUE072537T2/hu unknown
- 2016-02-01 JP JP2017559275A patent/JP6928768B2/ja active Active
- 2016-02-01 TW TW105103175A patent/TWI790191B/zh active
- 2016-02-01 US US15/012,355 patent/US10111836B2/en active Active
- 2016-02-01 EP EP16744263.1A patent/EP3250214B1/en active Active
- 2016-02-01 RS RS20250815A patent/RS67133B1/sr unknown
- 2016-02-01 ES ES16744263T patent/ES2899226T3/es active Active
- 2016-02-01 ES ES21192594T patent/ES3034734T3/es active Active
- 2016-02-01 EP EP21192594.6A patent/EP3981414B1/en active Active
- 2016-02-01 FI FIEP21192594.6T patent/FI3981414T3/fi active
- 2016-02-01 PT PT211925946T patent/PT3981414T/pt unknown
- 2016-02-01 LT LTEP21192594.6T patent/LT3981414T/lt unknown
- 2016-02-01 PL PL21192594.6T patent/PL3981414T3/pl unknown
- 2016-02-01 AU AU2016211186A patent/AU2016211186A1/en not_active Abandoned
- 2016-02-01 CA CA3225480A patent/CA3225480A1/en active Pending
- 2016-02-01 DK DK21192594.6T patent/DK3981414T3/da active
- 2016-02-01 MX MX2017009913A patent/MX390835B/es unknown
- 2016-02-01 TW TW110142380A patent/TW202228734A/zh unknown
- 2016-02-01 SM SM20250321T patent/SMT202500321T1/it unknown
- 2016-02-01 WO PCT/US2016/015917 patent/WO2016123603A2/en not_active Ceased
- 2016-02-01 HR HRP20251032TT patent/HRP20251032T1/hr unknown
-
2017
- 2017-07-31 MX MX2020012611A patent/MX2020012611A/es unknown
-
2018
- 2018-10-01 US US16/148,193 patent/US10272045B2/en active Active
-
2019
- 2019-03-12 US US16/299,214 patent/US10653628B2/en active Active
-
2020
- 2020-04-20 US US16/852,758 patent/US20210069115A1/en not_active Abandoned
-
2021
- 2021-06-07 AU AU2021203752A patent/AU2021203752B2/en active Active
- 2021-06-22 JP JP2021103196A patent/JP7539855B2/ja active Active
-
2023
- 2023-01-27 US US18/160,445 patent/US12364664B2/en active Active
- 2023-08-10 AU AU2023214307A patent/AU2023214307B2/en active Active
-
2024
- 2024-01-10 US US18/408,664 patent/US20240269076A1/en active Pending
- 2024-08-14 JP JP2024135193A patent/JP2024161468A/ja active Pending
-
2025
- 2025-10-29 AU AU2025259861A patent/AU2025259861A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390835B (es) | Composiciones liofilizadas de alta área de superficie que comprenden arsénico para administración oral en pacientes | |
| MD4643B1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| EA201890125A1 (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| MX2019008063A (es) | 17a, 21-diesteres de cortexolona para uso en el tratamiento de tumores. | |
| MX2015011752A (es) | Metodos para tratar cancer de pulmon. | |
| BR112015019064A2 (pt) | métodos de tratamento de melanoma | |
| MY184628A (en) | Afucosylated anti-fgfr2iiib antibodies | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| NZ726365A (en) | Combinations for treating cancers | |
| PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
| BR112015021097A2 (pt) | formulações de compostos orgânicos | |
| PH12018501292A1 (en) | Pharmaceutical compositions comprising phenylaminopyridine derviative | |
| MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. | |
| BR112014016723A2 (pt) | método para o tratamento de câncer de mama | |
| MX2016005900A (es) | Profarmaco mutuo que comprende acidos grasos de cadena corta y zebularina o 1'-ciano-citarabina para tratamiento del cancer. | |
| BR112018005494A2 (pt) | composto, composição farmacêutica, e, método de tratamento de um paciente com uma doença. | |
| BR112019025164A2 (pt) | Esquema de dosagem para tesetaxel e capecitabina | |
| NZ734201B2 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| NZ772450B2 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| AR100271A1 (es) | Compuestos de vegfr2 / ang2 | |
| WO2019108685A8 (en) | Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith | |
| MX2018013428A (es) | Composicion farmaceutica de comprimido en comprimido que comprende ciclofosfamida y capecitabina. | |
| MX2019013019A (es) | USO DE 3,16-DIACETADO DE 26-AZIDO-22-OXOCOLEST-5-3ß, 16ß-DIILO COMO AGENTE ANTICANCERIGENO. |